TCDAQ   $0.0095  3.16% Market Open


Current temperature: 0.00
ST: 0, Cor:

Analyst Recommendations:
Number of estimates
Target Price Mean
Mean unverified/preliminary /
Target Price Low / High /
Median / STD DEV /
ISIN US89610F1012
ceo Dr. Gerrit Klaerner Ph.D.
Website https://www.tricida.com
Tricida, Inc. operates as a pharmaceutical company. It focuses on the development and commercialization of veverimer (TRC101), a non-absorbed orally-administered polymer that has completed Phase III trial to treat metabolic acidosis in patients with chronic kidney disease by binding and removing acid from the gastrointestinal track. The company was incorporated in 2013 and is headquartered in South San Francisco, California. On January 11, 2023, Tricida, Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.